Stockreport
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Will the recent negative trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q1 Earnings in Line With Estimates, Sales Lag Allogene registered a loss of 38 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported a loss of 69 cents. ALLO recorded revenues of $0.02 million during the quarter, missing the Zacks Consensus Estimate of $0.04 million. Revenues were down 27% year over year. Quarter in Detail Research & development (R&D) expenses were $52.3 million, down 35% from the year-ago quarter's level. General and administrative (G&A) expenses declined 9% year over year to $17.3 million. Allogene had $397.3 million of cash, cash equivalents and investments as of
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse[GlobeNewswire]
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $11.00 price target on the stock.[MarketBeat]
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit[GlobeNewswire]
- More
ALLO
SEC Filings
SEC Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 144
- 6/11/24 - Form 3
- ALLO's page on the SEC website
- More